Skip to Main Content

Paper Details

Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Hypertension
13
2017
Heart Attack, amlodipine, antihypertensive, cardiovascular disease, chlorthalidone, doxazosin, hypertension, lisinopril, participants, stroke
Author NameAffiliation
Sanket S DhruvaFrom the Robert Wood Johnson Foundation Clinical Scholars Program (S.S.D., Yale School of Medicine, Yale School of Public Health, Yale University, CT (R.R.C.) The Center for Outcomes Research and Evaluation, H.M.K.) Veterans Affairs Connecticut Healthcare System, Wake Forest University School of Medicine, NC (C.D.F.) and University of Texas School of Public Health
Chenxi HuangFrom the Robert Wood Johnson Foundation Clinical Scholars Program (S.S.D., Yale School of Medicine, Yale School of Public Health, Yale University, CT (R.R.C.) The Center for Outcomes Research and Evaluation, H.M.K.) Veterans Affairs Connecticut Healthcare System, Wake Forest University School of Medicine, NC (C.D.F.) and University of Texas School of Public Health
Erica S SpatzFrom the Robert Wood Johnson Foundation Clinical Scholars Program (S.S.D., Yale School of Medicine, Yale School of Public Health, Yale University, CT (R.R.C.) The Center for Outcomes Research and Evaluation, H.M.K.) Veterans Affairs Connecticut Healthcare System, Wake Forest University School of Medicine, NC (C.D.F.) and University of Texas School of Public Health
Andreas CoppiFrom the Robert Wood Johnson Foundation Clinical Scholars Program (S.S.D., Yale School of Medicine, Yale School of Public Health, Yale University, CT (R.R.C.) The Center for Outcomes Research and Evaluation, H.M.K.) Veterans Affairs Connecticut Healthcare System, Wake Forest University School of Medicine, NC (C.D.F.) and University of Texas School of Public Health
Frederick WarnerFrom the Robert Wood Johnson Foundation Clinical Scholars Program (S.S.D., Yale School of Medicine, Yale School of Public Health, Yale University, CT (R.R.C.) The Center for Outcomes Research and Evaluation, H.M.K.) Veterans Affairs Connecticut Healthcare System, Wake Forest University School of Medicine, NC (C.D.F.) and University of Texas School of Public Health
Shu-Xia LiFrom the Robert Wood Johnson Foundation Clinical Scholars Program (S.S.D., Yale School of Medicine, Yale School of Public Health, Yale University, CT (R.R.C.) The Center for Outcomes Research and Evaluation, H.M.K.) Veterans Affairs Connecticut Healthcare System, Wake Forest University School of Medicine, NC (C.D.F.) and University of Texas School of Public Health
Harlan M KrumholzFrom the Robert Wood Johnson Foundation Clinical Scholars Program (S.S.D., Yale School of Medicine, Yale School of Public Health, Yale University, CT (R.R.C.) The Center for Outcomes Research and Evaluation, H.M.K.) Veterans Affairs Connecticut Healthcare System, Wake Forest University School of Medicine, NC (C.D.F.) and University of Texas School of Public Health
Harlan M KrumholzFrom the Robert Wood Johnson Foundation Clinical Scholars Program (S.S.D., Yale School of Medicine, Yale School of Public Health, Yale University, CT (R.R.C.) The Center for Outcomes Research and Evaluation, H.M.K.) Veterans Affairs Connecticut Healthcare System, Wake Forest University School of Medicine, NC (C.D.F.) and University of Texas School of Public Health
  • 1 - 8

Datasets